<DOC>
	<DOC>NCT00740168</DOC>
	<brief_summary>Bevacizumab might influence the dynamic vessel function after being administered intravenously.</brief_summary>
	<brief_title>Bevacizumab Treatment and Retinal Vessel Monitoring</brief_title>
	<detailed_description>By monitoring different vessel and circulation parameters (e.g. dynamic retinal vessel analyzer) the study will clarify the potential hemodynamic effects of bevacizumab.</detailed_description>
	<mesh_term>Bevacizumab</mesh_term>
	<criteria>patients who wish and need bevacizumab treatment for underlying disease previous bevacizumab treatment known eye disease, eye surgery or eye trauma in history myopia &gt;2.0 dpt hyperopia &gt; +2.0 dpt. relevant media opacity of the lens acute heart disease, ischemic insult, proven coronary heart disease cardiac arrhythmia or vessel anomalies seizure disorder or episode in history migraine treatment with corticosteroids within 4 weeks before study inclusion intake of vasoactive drugs like AT1 or glitazone pregnancy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>bevacizumab</keyword>
	<keyword>cancer</keyword>
</DOC>